FDA Inspection 1250648 — University of Texas MD Anderson Cancer Center
The FDA completed an inspection of University of Texas MD Anderson Cancer Center on September 16, 2024 in Houston, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 16, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Houston, TX (United States)